Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
Crossref DOI link: https://doi.org/10.1007/s40273-017-0590-5
Published Online: 2017-11-27
Published Print: 2018-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mallya, Usha G.
Boklage, Susan H.
Koren, Andrew
Delea, Thomas E.
Mullins, C. Daniel
Funding for this research was provided by:
Regeneron Pharmaceuticals
Sanofi
License valid from 2017-11-27